Posted by Michael Wonder on 06 Jul 2020
ICER posts draft scoping document on high cholesterol
6 July 2020 - Document open to public comment until 24 July 2020.
The Institute for Clinical and Economic Review has posted a draft scoping document outlining a planned review of the comparative clinical effectiveness and value of treatments for high cholesterol, including inclisiran (Novartis), bempedoic acid (Nexletol, Esperion Therapeutics) and bempedoic acid/ezetimibe (Nexlizet, Esperion Therapeutics).
